Mirum Pharmaceuticals (MIRM) Free Cash Flow (2019 - 2026)
Mirum Pharmaceuticals' quarterly Free Cash Flow came in at -$229.4 million in Q1 2026, down 11359.89% year-on-year from N/an in Q1 2025, and down 4296.58% quarter-over-quarter from $5.5 million in Q4 2025.
Mirum Pharmaceuticals has reported Free Cash Flow for 8 years, with the latest figure at -$229.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 11359.89% year-over-year to -$229.4 million; the trailing twelve-month figure through Mar 2026 stood at -$172.6 million (down 2092.81% YoY), and the FY2025 full-year result was $54.9 million, up 488.01% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$229.4 million, down from $5.5 million in the prior quarter.
- The five-year high for Free Cash Flow was $39.5 million in Q3 2025, with the low at -$229.4 million in Q1 2026.
- Average Free Cash Flow over 5 years is -$21.0 million, with a median of -$16.6 million recorded in 2023.
- Year-over-year, Free Cash Flow surged 938.5% in 2025 and slumped 11359.89% in 2026.
- Tracing MIRM's Free Cash Flow over 5 years: stood at -$34.5 million in 2022, then soared by 51.85% to -$16.6 million in 2023, then surged by 69.38% to -$5.1 million in 2024, then jumped by 207.45% to $5.5 million in 2025, then tumbled by 4296.58% to -$229.4 million in 2026.
- The last three Free Cash Flow figures came in at -$229.4 million (Q1 2026), $5.5 million (Q4 2025), and $39.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Mirum Pharmaceuticals | 5.97 Bn | 5.59 Bn | 131.08 Mn | -229.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -229.43 Mn |
| Mar 31, 2026 | -229.43 Mn |
| Dec 31, 2025 | 5.47 Mn |
| Dec 31, 2025 | 5.47 Mn |
| Sep 30, 2025 | 39.49 Mn |
| Sep 30, 2025 | 39.49 Mn |
| Jun 30, 2025 | 11.91 Mn |
| Jun 30, 2025 | 11.91 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | -5.09 Mn |
| Dec 31, 2024 | -5.09 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | -4.58 Mn |
| Jun 30, 2024 | -4.58 Mn |
| Mar 31, 2024 | 15.20 Mn |
| Mar 31, 2024 | 15.20 Mn |
| Dec 31, 2023 | -16.62 Mn |
| Dec 31, 2023 | -16.62 Mn |
| Sep 30, 2023 | -18.22 Mn |
| Sep 30, 2023 | -18.22 Mn |
| Jun 30, 2023 | -17.40 Mn |
| Jun 30, 2023 | -17.40 Mn |
| Mar 31, 2023 | -18.82 Mn |
| Mar 31, 2023 | -18.82 Mn |
| Dec 31, 2022 | -34.51 Mn |
| Dec 31, 2022 | -34.51 Mn |
| Sep 30, 2022 | -26.04 Mn |
| Sep 30, 2022 | -26.04 Mn |
| Jun 30, 2022 | -20.19 Mn |
| Jun 30, 2022 | -20.19 Mn |
| Mar 31, 2022 | -39.67 Mn |
| Mar 31, 2022 | -39.67 Mn |
| Dec 31, 2021 | -33.15 Mn |
| Dec 31, 2021 | -33.15 Mn |
| Sep 30, 2021 | -34.22 Mn |
| Sep 30, 2021 | -34.22 Mn |
| Jun 30, 2021 | -40.20 Mn |
| Jun 30, 2021 | -40.20 Mn |
| Mar 31, 2021 | -25.21 Mn |
| Mar 31, 2021 | -25.21 Mn |
| Dec 31, 2020 | -36.31 Mn |
| Dec 31, 2020 | -36.31 Mn |
| Sep 30, 2020 | -17.50 Mn |
| Sep 30, 2020 | -17.50 Mn |
| Jun 30, 2020 | -17.05 Mn |
| Jun 30, 2020 | -17.05 Mn |
| Mar 31, 2020 | -18.45 Mn |
| Mar 31, 2020 | -18.45 Mn |
| Dec 31, 2019 | -13.94 Mn |
| Dec 31, 2019 | -13.94 Mn |
| Sep 30, 2019 | -15.22 Mn |
| Sep 30, 2019 | -15.22 Mn |
| Jun 30, 2019 | -8.02 Mn |
| Jun 30, 2019 | -8.02 Mn |
| Mar 31, 2019 | -2.47 Mn |
| Mar 31, 2019 | -2.47 Mn |